retatrutide medicamento Promises Big Weight Loss, but Safety Remains a Question Retatrutida (Retatrutide) · investigación |
Description
I think many clinicians misunderstand why people lose muscle on GLP1 agonists
Glucagon receptor activation drives energy expenditure through thermogenesis, promotes hepatic fat oxidation, and enhances lipolysis in ways that GLP-1 activation alone simply cannot achieve
Wegovy was approved in 2021, and the rest is history
Despite it being rare, patients and doctors should be acutely aware of the side effects involved. As a clinician, how should I manage medication-induced gastroparesis
Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial PMID: 37366315 N Engl J Med
